BIND Therapeutics
Founded Year
2006Stage
Asset Sale | AssetsPurchasedTotal Raised
$127.98MRevenue
$0000About BIND Therapeutics
BIND Therapeutics, formerly BIND Biosciences, is a biopharmaceutical company leveraging its medicinal nanoengineering platform to design, engineer and manufacture targeted therapeutics. Medicinal nanoengineering complements medicinal chemistry to enable predictable, cost-effective, and rapid development of products with efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications, or life cycle extension for mid- and late-stage products. BIND's initial product development efforts were in the areas of oncology, cardiovascular disorders, inflammatory disease, and RNAi therapeutics.
Missing: BIND Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BIND Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BIND Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BIND Therapeutics is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
BIND Therapeutics Patents
BIND Therapeutics has filed 46 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/18/2016 | 9/11/2018 | Experimental cancer drugs, Polymers, Amines, Antineoplastic drugs, Monoclonal antibodies | Grant |
Application Date | 2/18/2016 |
|---|---|
Grant Date | 9/11/2018 |
Title | |
Related Topics | Experimental cancer drugs, Polymers, Amines, Antineoplastic drugs, Monoclonal antibodies |
Status | Grant |
Latest BIND Therapeutics News
Dec 16, 2021
December 16, 2021 08:00 AM Eastern Standard Time WALTHAM, Mass.--( BUSINESS WIRE )-- Palleon Pharmaceuticals , a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced the appointment of Denis Patrick, Ph.D., to its Board of Directors. Dr. Patrick is Vice President and Head of Partnering Innovation at Pfizer and a Managing Partner at Pfizer Ventures, the venture capital arm of Pfizer Inc. “Denis’ experience at multiple major biopharmaceutical companies and his knowledge of oncologic drug discovery will contribute greatly to Palleon’s mission to develop better therapies for patients,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “We are thrilled to welcome him to our Board and look forward to collaborating with him as we continue to move forward with the company’s drug discovery and development initiatives into 2022 and beyond. Denis will replace Dr. Nikola Trbovic, whom we would like to thank for his many contributions to Palleon during 2021.” Currently, Dr. Patrick serves as a Board member of FoRx Therapeutics, Metabomed, Mission Therapeutics, and EvolveImmune Therapeutics. Prior to joining Pfizer Ventures, Dr. Patrick served as Head of Oncology Licensing for Worldwide R&D at Pfizer, where he executed the acquisitions of Medivation and BIND Therapeutics and secured research licenses with eight biopharmaceutical companies. Prior to his work at Pfizer, Dr. Patrick served as Director of Oncology Scientific Licensing and Business Development at GlaxoSmithKline, where he was responsible for evaluating clinical and pre-clinical oncologic drugs for potential in-licensing. He began his career as a research scientist at Merck in the drug discovery sector for cancer. Dr. Patrick earned his Ph.D. in biochemistry from the University of Pennsylvania. “Palleon is charting new possibilities in immuno-oncology thanks to their scientific leadership in the field of glycobiology, and it’s an exciting time to join those efforts,” said Dr. Patrick. “As a member of the Board, I look forward to collaborating with this exceptional team to improve and extend the lives of patients suffering from serious diseases.” About Palleon Pharmaceuticals Palleon Pharmaceuticals is the leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. The company’s proprietary platforms overcome scientific hurdles that limited progress in the glycobiology field to create novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program in oncology, E-602, is an enzymatic degrader of immunosuppressive sialoglycans on tumors and immune cells which is expected to enter clinical testing in refractory cancer patients in early 2022. www.palleonpharma.com . Contacts
BIND Therapeutics Frequently Asked Questions (FAQ)
When was BIND Therapeutics founded?
BIND Therapeutics was founded in 2006.
Where is BIND Therapeutics's headquarters?
BIND Therapeutics's headquarters is located at 325 Vassar Street, Cambridge.
What is BIND Therapeutics's latest funding round?
BIND Therapeutics's latest funding round is Asset Sale.
How much did BIND Therapeutics raise?
BIND Therapeutics raised a total of $127.98M.
Who are the investors of BIND Therapeutics?
Investors of BIND Therapeutics include Pfizer, Flagship Pioneering, Polaris Partners, Rusnano, ARCH Venture Partners and 8 more.
Who are BIND Therapeutics's competitors?
Competitors of BIND Therapeutics include Catalyst Biosciences, Cerecin, MaxCyte, Clinipace, Array Biopharma, AngioChem, Genable Technologies, Probiodrug, ViroPharma, Zyngenia and 17 more.
Compare BIND Therapeutics to Competitors
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Abunda, is a stealth mode healthcare company incubated by Burrill & Company
Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.
Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.